GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IPI Legacy Liquidation Co (OTCPK:IMPLQ) » Definitions » ROIC %

IPI Legacy Liquidation Co (IPI Legacy Liquidation Co) ROIC % : -41.22% (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is IPI Legacy Liquidation Co ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. IPI Legacy Liquidation Co's annualized return on invested capital (ROIC %) for the quarter that ended in Sep. 2023 was -41.22%.

As of today (2024-05-15), IPI Legacy Liquidation Co's WACC % is 19.20%. IPI Legacy Liquidation Co's ROIC % is -116.11% (calculated using TTM income statement data). IPI Legacy Liquidation Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


IPI Legacy Liquidation Co ROIC % Historical Data

The historical data trend for IPI Legacy Liquidation Co's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IPI Legacy Liquidation Co ROIC % Chart

IPI Legacy Liquidation Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22
ROIC %
-696.74 -593.03 -765.21 -611.15

IPI Legacy Liquidation Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -586.29 -449.30 -475.45 -90.42 -41.22

Competitive Comparison of IPI Legacy Liquidation Co's ROIC %

For the Biotechnology subindustry, IPI Legacy Liquidation Co's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IPI Legacy Liquidation Co's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IPI Legacy Liquidation Co's ROIC % distribution charts can be found below:

* The bar in red indicates where IPI Legacy Liquidation Co's ROIC % falls into.



IPI Legacy Liquidation Co ROIC % Calculation

IPI Legacy Liquidation Co's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2022 is calculated as:

ROIC % (A: Dec. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2021 ) + Invested Capital (A: Dec. 2022 ))/ count )
=-83.184 * ( 1 - 0% )/( (9.365 + 17.857)/ 2 )
=-83.184/13.611
=-611.15 %

where

IPI Legacy Liquidation Co's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Sep. 2023 is calculated as:

ROIC % (Q: Sep. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Sep. 2023 ))/ count )
=-51.244 * ( 1 - 0% )/( (121.716 + 126.938)/ 2 )
=-51.244/124.327
=-41.22 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IPI Legacy Liquidation Co  (OTCPK:IMPLQ) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, IPI Legacy Liquidation Co's WACC % is 19.20%. IPI Legacy Liquidation Co's ROIC % is -116.11% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


IPI Legacy Liquidation Co ROIC % Related Terms

Thank you for viewing the detailed overview of IPI Legacy Liquidation Co's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


IPI Legacy Liquidation Co (IPI Legacy Liquidation Co) Business Description

Traded in Other Exchanges
N/A
Address
201 Elliott Avenue West, Suite 260, Seattle, WA, USA, 98119
Impel Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. The company is developing an approach to drug delivery that administers specific formulations of drugs deep into the vascular-rich upper nasal space, a gateway for therapeutic administration of a versatile range of molecules and formulations.
Executives
Vivo Capital Fund Viii, L.p. 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Michael Wayne Kalb officer: CFO 24 LUCILLE LANE, DIX HILLS NY 11746
Darren S Cline director 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Rajiv Amin officer: VP, Controller & Interim CFO C/O IMPEL PHARMACEUTICALS INC., 201 ELLIOTT AVENUE WEST, STE 260, SEATTLE WA 98119
Timothy S Nelson director 1024 BUBB ROAD, CUPERTINO CA 950144166
Adrian Adams director, officer: COB, CEO and President C/O AUXILIUM PHARMACEUTICALS, INC., 640 LEE ROAD, CHESTERBROOK PA 19355
Venbio Global Strategic Fund Ii L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
5am Opportunities I, L.p. 10 percent owner 501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I (gp), Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures V, L.p. 10 percent owner 2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
Kkr Healthcare Strategic Growth Fund L.p. 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
Norwest Venture Partners Xiv, Lp 10 percent owner 525 UNIVERSITY AVENUE, SUITE 800, PALO ALTO CA 94301
Kkr Hcsg Gp Llc 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
5am Partners V, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kkr Associates Hcsg L.p. 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019